Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.58 |
| ▸ | GLP1R | P43220 | 8/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.53 |
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25542893 | 1.00 | NOD1 (0.58) | NOD1GLP1RLPAR3CASP2SIRT2 | |
| SCHEMBL25542895 | 1.00 | NOD1 (0.58) | NOD1GLP1RLPAR3CASP2SIRT2 | |
| SCHEMBL25542898 | 1.00 | NOD1 (0.58) | NOD1GLP1RLPAR3CASP2SIRT2 | |
| SCHEMBL25542908 | 1.00 | NOD1 (0.58) | NOD1GLP1RLPAR3CASP2SIRT2 | |
| SCHEMBL16264552 | 1.00 | NOD1 (0.58) | NOD1GLP1RLPAR3CASP2SIRT2 | |
| SCHEMBL19308433 | 1.00 | NOD1 (0.58) | NOD1GLP1RLPAR3CASP2SIRT2 | |
| SCHEMBL25542902 | 1.00 | NOD1 (0.58) | NOD1GLP1RLPAR3CASP2SIRT2 | |
| SCHEMBL16244936 | 0.94 | FAAH (0.54) | NOD1GLP1RLPAR3CASP2SIRT2 | |
| SCHEMBL25549709 | 0.93 | EPHX2 (0.61) | LPAR1EPHX2 | |
| SCHEMBL25549652 | 0.93 | EPHX2 (0.61) | LPAR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NSUN2, NSUN3, POLM | NOD1 1668/4885GLP1R 1506/4885LPAR3 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.